Use of the CXCR4 inhibitor plerixafor was shown to be well tolerated in multiple myeloma patients [313] and in metastatic colorectal and pancreatic cancer patients where it resulted in a tumor cell gene signature suggestive of response to immune-checkpoint mediated therapies [314]. Here, CXCR4 is linked to neoplasm.